Capsid News and Research

RSS

Breakthrough reveals how viruses efficiently pack genetic material

Researchers at San Diego State University and Michigan State University are shedding new light on how viruses meticulously pack their genetic material - a breakthrough that could help researchers engineer antivirals and gene therapies.

2 Sep 2025

Breakthrough gene therapy reverses genetic deafness across age groups

Using gene therapy to treat hereditary deafness is safe and effective in both children and adults, according to new findings from a multicenter clinical trial.

22 Jul 2025

Mass photometry recognized by U.S. Pharmacopeia in new AAV reference standards for gene therapy quality

Refeyn, the company behind pioneering mass photometry technology, announces that mass photometry has been recognized by the U.S. Pharmacopeia (USP)—and referenced in the new draft USP general chapter <1067>—as a key orthogonal method for characterizing USP's new adeno-associated virus (AAV) reference standards.

19 Jun 2025

New insights into HIV-1 capsid disruption open doors for novel therapies

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host nuclear pore complexes (NPCs).

13 May 2025

Long-acting HIV drug emerges from decades of research and advocacy

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

8 May 2025

Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).

From Sino Biological Inc. 12 Mar 2025

New HIV therapy lenacapavir shows high efficacy in Ugandan population

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

19 Feb 2025

From crude lysate to purity with high-precision AAV capsid measurement with Bio-Rad's new ddPCR Kit

Accurately quantify AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit—offering reliable, efficient, and precise measurement to streamline your research workflows.

From Bio-Rad Laboratories 19 Nov 2024

Engineered virus-like particles evolve for superior gene delivery efficiency

Researchers developed a barcoded directed evolution system for engineered virus-like particles (eVLPs), creating a fifth-generation (v5) eVLP with enhanced production, transduction, and gene-editing efficiency. This system could pave the way for improved gene delivery vehicles in therapeutic applications.

17 Nov 2024

New approach for cervical cancer vaccines based on microsphere-encapsulated peptides

Infection with HPV16, a high-risk human papillomavirus (HPV), can cause cervical cancer in humans. These infections carry a high risk of morbidity and mortality globally in females.

29 Oct 2024

Structural biology reveals secrets of DEV phage infection

The viruses that infect bacteria are the most abundant biological entities on the planet. For example, a recent simple study of 92 showerheads and 36 toothbrushes from American bathrooms found more than 600 types of bacterial viruses, commonly called bacteriophages or phages.

22 Oct 2024

Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the AAV Edge System, a comprehensive suite of tools for adeno-associated viral (AAV) gene therapy design and manufacturing.

18 Sep 2024

New consensus on assessing carcinogenic risks of gene therapies

A new article in the peer-reviewed journal Human Gene Therapy describes the consensus reached by invited experts who participated in a meeting to evaluate the potential carcinogenicity of gene therapies.

30 Aug 2024

mRNA therapy shows promise for maple syrup urine disease

Researchers from the University of Pennsylvania, Perelman School of Medicine, Gene Therapy Program, and Moderna, have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy significantly extended survival and reduced serum leucine levels in a mouse model of maple syrup urine disease (MSUD).

22 Aug 2024

Machine learning revolutionizes gene delivery

Gene therapy could potentially cure genetic diseases but it remains a challenge to package and deliver new genes to specific cells safely and effectively. Existing methods of engineering one of the most commonly used gene-delivery vehicles, adeno-associated viruses (AAV), are often slow and inefficient.

9 Aug 2024